Prenetics Global (NASDAQ:PRE) Trading 3.8% Higher

Prenetics Global Limited (NASDAQ:PRE)’s share price traded up 3.8% during trading on Thursday . The company traded as high as $5.36 and last traded at $4.97. 188,526 shares changed hands during trading, an increase of 77% from the average session volume of 106,356 shares. The stock had previously closed at $4.79.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald cut their price target on Prenetics Global from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, April 4th.

Prenetics Global Stock Down 7.2 %

The firm has a market capitalization of $42.12 million, a PE ratio of -0.96 and a beta of -0.11. The stock’s fifty day simple moving average is $4.40 and its 200 day simple moving average is $4.81.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.52) EPS for the quarter. Prenetics Global had a negative return on equity of 11.15% and a negative net margin of 193.60%. The company had revenue of $5.43 million during the quarter. On average, analysts predict that Prenetics Global Limited will post -3.59 EPS for the current year.

Hedge Funds Weigh In On Prenetics Global

A hedge fund recently raised its stake in Prenetics Global stock. Nomura Holdings Inc. lifted its stake in Prenetics Global Limited (NASDAQ:PRE) by 140.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 193,963 shares of the company’s stock after buying an additional 113,288 shares during the quarter. Nomura Holdings Inc. owned approximately 2.12% of Prenetics Global worth $1,146,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.